Author:
Teoh P J,Chung T H,Sebastian S,Choo S N,Yan J,Ng S B,Fonseca R,Chng W J
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference50 articles.
1. Stühmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C et al. Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood 2005; 106: 3609–3617.
2. Yuregir OO, Sahin FI, Yilmaz Z, Kizilkilic E, Karakus S, Ozdogu H . Fluorescent in situ hybridization studies in multiple myeloma. Hematology 2009; 14: 90–94.
3. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H . MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biol Ther 2010; 9: 937–945.
4. Drach J, Ackermann J, Fritz E, Kromer E, Schuster R, Gisslinger H et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood 1998; 92: 802–809.
5. Vogelstein B, Lane D, Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310.